Objective: To evaluate the efficacy and safety of transarterial embolization (TAE) in the management of hematuria secondary to congenital renal arteriovenous malformations (AVM). Patients and Methods: Between May 2007 and February 2012, 6 patients with congenital AVM treated with TAE were analyzed retrospectively, followed by a brief review of TAE in the treatment of congenital AVM. Clinical records with respect to general conditions, location, embolic materials, complications and overall outcome were collected from the original hospital charts and outpatient medical records. Results: Three patients with AVM were confirmed by contrast-enhanced CT scans, and the other 3 patients were detected by renal angiography. TAE was performed with steel coils in 2 patients and n-butyl-2-cyanoacrylate (NBCA) in 4 patients. After a mean follow-up of 22 months, no serious adverse effects were observed in all patients. There were no complaints of hematuria at the end of the follow-up period. Conclusion: For unexplained massive hematuria, congenital renal AVM needs to be considered as a differential diagnosis. Selective renal angiography and embolization should be recommended as the first choice to treat massive hematuria secondary to congenital renal AVM.

Keywords:
Transarterial embolization, Hematuria, Congenital arteriovenous malformation, n-Butyl-2-cyanoacrylate, Coil
1.
Cura M, Elmerhi F, Suri R, Bugnone A, Dalsaso T: Vascular malformations and arteriovenous fistulas of the kidney. Acta Radiol 2010;51:144-149.
2.
Wetter A, Schlunz-Hendann M, Meila D, Rohde D, Brassel F: Endovascular treatment of a renal arteriovenous malformation with Onyx. Cardiovasc Intervent Radiol 2012;35:211-214.
3.
Crotty KL, Orihuela E, Warren MM: Recent advances in the diagnosis and treatment of renal arteriovenous malformations and fistulas. J Urol 1993;150:1355-1359.
4.
Cho KJ, Stanley JC: Non-neoplastic congenital and acquired renal arteriovenous malformations and fistulas. Radiology 1978;129:333-343.
5.
Miranda Utrera N, Pamplona Casamayor M, Guerrero Ramos F, Leiva Galvis O: Congenital renal arteriovenous malformation: the value of magnetic resonance imaging for diagnosis and intravascular management. Actas Urol Esp 2010;34:215-217.
6.
Tarif N, Mitwalli AH, Al Samayer SA, Abu-Aisha H, Memon NA, Sulaimani F, Alam A, Al Wakeel JS: Congenital renal arteriovenous malformation presenting as severe hypertension. Nephrol Dial Transplant 2002;17:291-294.
7.
Carrafiello G, Laganà D, Peroni G, Mangini M, Fontana F, Mariani D, Piffaretti G, Fugazzola C: Gross hematuria caused by a congenital intrarenal arteriovenous malformation: a case report. J Med Case Rep 2011;5:510.
8.
Hyams ES, Pierorazio P, Proteek O, Sukumar S, Wagner AA, Mechaber JL, Rogers C, Kavoussi L, Allaf M: Iatrogenic vascular lesions after minimally invasive partial nephrectomy: a multi-institutional study of clinical and renal functional outcomes. Urology 2011;78:820-826.
9.
Kubota Y, Tsuchiya T, Kamei S, Takahashi Y, Ehara H, Deguchi T, Goshima S, Kanematsu M: Transcatheter arterial embolization with n-butyl-2-cyanoacrylate (Hystoacryl) in two treatments for huge renal arteriovenous malformation. Hinyokika Kiyo 2007;53:307-310.
10.
Chatziioannou A, Mourikis D, Kalaboukas K, Ladopoulos C, Magoufis G, Primetis E, Katsenis K, Vlahos L: Endovascular treatment of renal arteriovenous malformations. Urol Int 2005;74:89-91.
11.
Defreyne L, Govaere F, Vanlangenhove P, Derie A, Kunnen M: Cirsoid renal arteriovenous malformation treated by endovascular embolization with n-butyl 2-cyanoacrylate. Eur Radiol 2000;10:772-775.
12.
Rizk GK, Atallah NK, Bridi GI: Renal arteriovenous fistula treated by catheter embolization. Br J Radiol 1973;46:222-224.
13.
Ogi S, Fukumitsu N, Tsuchida D, Uchiyama M, Mori Y, Hasegawa N: The role of renal scintigraphy in renal arteriovenous malformation treated by transcatheter arterial embolization. Clin Nucl Med 2002;27:877-882.
14.
Kamai T, Saito K, Hirokawa M, Tukamoto H, Ashida H: A case of gross hematuria arising during embolization for renal arteriovenous malformation. Urol Int 1997;58:55-57.
15.
Takebayashi S, Hosaka M, Kubota Y, Ishizuka E, Iwasaki A, Matsubara S: Transarterial embolization and ablation of renal arteriovenous malformations: efficacy and damages in 30 patients with long-term followup. J Urol 1998;159:696-701.
16.
Macdonald S, Edwards RD: Embolisation of renal arteriovenous malformation (AVM) in pregnancy. Scott Med J 2001;46:52-53.
17.
Sountoulides P, Zachos I, Paschalidis K, Asouhidou I, Fotiadou A, Bantis A, Palasopoulou M, Podimatas T: Massive hematuria due to a congenital renal arteriovenous malformation mimicking a renal pelvis tumor: a case report. J Med Case Rep 2008;2:144.
18.
Lette J, Tardif L, Beaudry C, Lassonde J: Large renal arteriovenous malformation: scintigraphic evaluation and therapeutic embolization. Can Assoc Radiol J 1992;43:381-384.
19.
Yoon JW, Koo JR, Baik GH, Kim JB, Kim DJ, Kim HK: Erosion of embolization coils and guidewires from the kidney to the colon: delayed complication from coil and guidewire occlusion of renal arteriovenous malformation. Am J Kidney Dis 2004;43:1109-1112.
20.
Allione A, Pomero F, Valpreda S, Porta M, Mallone R, Rabbia C, Cavallo Perin P: Worsening of hypertension in a pregnant woman with renal arteriovenous malformation: a successful superselective embolization after delivery. Clin Nephrol 2003;60:211-213.
21.
Wong C, Leveillee RJ, Yrizarry JM, Kirby K: Arteriovenous malformation mimicking a renal-cell carcinoma. J Endourol 2002;16:685-686.
22.
Durack JC, Wang JH, Schneider DB, Kerlan RK: Vena cava filter scaffold to prevent migration of embolic materials in the treatment of a massive renal arteriovenous malformation. J Vasc Interv Radiol 2012;23:413-416.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.